Quantcast
Home > Quotes > OVID

Ovid Therapeutics Inc. Common Stock (OVID) Quote & Summary Data

OVID 
$4.56
*  
0.05
1.11%
Get OVID Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading OVID now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
23.5
Today's High / Low
$ 4.67 / $ 4.19
Share Volume
21,376
50 Day Avg. Daily Volume
75,435
Previous Close
$ 4.51
52 Week High / Low
$ 12.44 / $ 4.16
Market Cap
112,422,760
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.05
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.5

Intraday Chart

Shares Traded

Share Volume:
21,376
50 Day Avg. Daily Volume:
75,435

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.05

Trading Range

The current last sale of $4.56 is 9.62% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.67 $ 12.44
 Low: $ 4.19 $ 4.16

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. We believe these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years; yet has remained underappreciated by the industry. Our experienced team began with a vision to integrate the biology and symptomology of rare neurological conditions to employ innovative research and clinical strategies for the development of our drug candidates. Based on recent scientific advances in genetics and the biological pathways of the brain, we created a proprietary map of disease-relevant pathways and used it to identify and acquire novel compounds for the treatment of rare neurological disorders. We are executing on our strategy by in-licensing and collaborating with leading biopharmaceutical companies and academic institutions.  ... More ...  


Risk Grade

Where does OVID fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.46
Open Date:
Nov. 16, 2018
Close Price:
$ 4.51
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x